What changed
$XPEV — AVOID 📊 | 6 MONTHS THESIS
🎯 latest | Rev $10.4B | EPS $-1.76 vs $-1.11 🔴
💡 The market is pricing a recovery that is unlikely to materialize given widening losses, pricing pressure, and weak demand. The recent miss suggests estimates haven't fully reset; consensus still expects a path to profitability that will be delayed.
📉 Reward/risk: 0.5:1
🏢 Business Quality: 3 — XPeng has some technology differentiation but lacks scale, faces intense competition, and is burning cash with no clear path to positive free cash flow./10
📊 Valuation: rich — based on peer P/E band (8.0x-28.0x), even with optimistic forward earnings, base target $8.4 (14.6x) implies 32.7% downside from current...
🔮 Catalyst: July Q3 delivery report
💰 Entry: $12.48, stop $14.0, target $8.4
📊 Our read: AVOID. Full analysis →
https://stockduty.xyz/s/XPEV0624